{"component": "definition", "props": {"groups": [{"size": 107, "snippet": "or \u201cGLP\u201d will mean the then current standards for laboratory activities for pharmaceuticals, as set forth in the FDA\u2019s GLP regulations and/or ICH guidelines and applicable regulations.", "samples": [{"hash": "b7xhnxmHZEn", "uri": "/contracts/b7xhnxmHZEn#good-laboratory-practice", "label": "Collaboration and License Agreement", "score": 26.1444225311, "published": true}, {"hash": "dD10JSz0mAA", "uri": "/contracts/dD10JSz0mAA#good-laboratory-practice", "label": "Collaboration and License Agreement (Regulus Therapeutics Inc.)", "score": 25.1587944031, "published": true}, {"hash": "aMOpmtelPSL", "uri": "/contracts/aMOpmtelPSL#good-laboratory-practice", "label": "Collaboration and License Agreement (Regulus Therapeutics Inc.)", "score": 23.6255989075, "published": true}], "snippet_links": [{"key": "current-standards", "type": "clause", "offset": [28, 45]}, {"key": "laboratory-activities", "type": "clause", "offset": [50, 71]}, {"key": "the-fda", "type": "clause", "offset": [109, 116]}, {"key": "ich-guidelines", "type": "definition", "offset": [142, 156]}, {"key": "applicable-regulations", "type": "definition", "offset": [161, 183]}], "hash": "155356979fb91108ac968870a8a043e7", "id": 1}, {"size": 41, "snippet": "means the applicable then-current standards for laboratory activities for pharmaceuticals or biologicals, as set forth in the Act and any regulations or guidance documents promulgated thereunder, as amended from time to time, together with any similar standards of good laboratory practice as are required by any Regulatory Authority in the Territory.", "samples": [{"hash": "6w0E2tStRUF", "uri": "/contracts/6w0E2tStRUF#good-laboratory-practice", "label": "License and Research Collaboration Agreement (Opko Health, Inc.)", "score": 34.3333320618, "published": true}, {"hash": "75lW3FVeHkz", "uri": "/contracts/75lW3FVeHkz#good-laboratory-practice", "label": "Research Collaboration and Exclusive License Agreement (Janux Therapeutics, Inc.)", "score": 32.3785095215, "published": true}, {"hash": "fe5l3cLqzRk", "uri": "/contracts/fe5l3cLqzRk#good-laboratory-practice", "label": "Exclusive License and Research Collaboration Agreement (Artiva Biotherapeutics, Inc.)", "score": 32.266254425, "published": true}], "snippet_links": [{"key": "the-applicable", "type": "clause", "offset": [6, 20]}, {"key": "current-standards", "type": "clause", "offset": [26, 43]}, {"key": "laboratory-activities", "type": "clause", "offset": [48, 69]}, {"key": "the-act", "type": "clause", "offset": [122, 129]}, {"key": "guidance-documents", "type": "definition", "offset": [153, 171]}, {"key": "as-amended", "type": "definition", "offset": [196, 206]}, {"key": "from-time-to-time", "type": "clause", "offset": [207, 224]}, {"key": "required-by", "type": "definition", "offset": [297, 308]}, {"key": "regulatory-authority", "type": "definition", "offset": [313, 333]}, {"key": "in-the-territory", "type": "clause", "offset": [334, 350]}], "hash": "c8772b239ca2effd3f4d31da75a00183", "id": 2}, {"size": 36, "snippet": "means the current standards for laboratory activities for pharmaceuticals, as set forth in the FDA\u2019s Good Laboratory Practice regulations or the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development (\u201cOECD\u201d), as amended from time to time, and such standards of good laboratory practice as are required by the EMA and other organizations and governmental agencies in Major EU Countries, to the extent such standards are not less stringent than United States Good Laboratory Practice.", "samples": [{"hash": "8BT2Uq1Acy6", "uri": "/contracts/8BT2Uq1Acy6#good-laboratory-practice", "label": "License Agreement (Seattle Genetics Inc /Wa)", "score": 29.3148536682, "published": true}, {"hash": "5CN37mgTRfI", "uri": "/contracts/5CN37mgTRfI#good-laboratory-practice", "label": "License Agreement (Oncothyreon Inc.)", "score": 26.1854896545, "published": true}, {"hash": "e1A15lwsi83", "uri": "/contracts/e1A15lwsi83#good-laboratory-practice", "label": "License Agreement (Array Biopharma Inc)", "score": 26.0924034119, "published": true}], "snippet_links": [{"key": "current-standards", "type": "clause", "offset": [10, 27]}, {"key": "laboratory-activities", "type": "clause", "offset": [32, 53]}, {"key": "the-fda", "type": "clause", "offset": [91, 98]}, {"key": "the-organization", "type": "definition", "offset": [184, 200]}, {"key": "and-development", "type": "clause", "offset": [227, 242]}, {"key": "as-amended", "type": "definition", "offset": [253, 263]}, {"key": "from-time-to-time", "type": "clause", "offset": [264, 281]}, {"key": "required-by", "type": "definition", "offset": [337, 348]}, {"key": "other-organizations", "type": "clause", "offset": [361, 380]}, {"key": "governmental-agencies", "type": "clause", "offset": [385, 406]}, {"key": "major-eu-countries", "type": "definition", "offset": [410, 428]}, {"key": "to-the-extent", "type": "clause", "offset": [430, 443]}, {"key": "united-states-good-laboratory-practice", "type": "definition", "offset": [487, 525]}], "hash": "284d023b282d3f6e8c146ab32fac636b", "id": 3}, {"size": 12, "snippet": "means a practice as defined in point 2.1 of Annex I to Directive 2004/10/EC of the European Parliament and of the Council of 11 February 2004 on the harmonisation of laws, regulations and administrative provisions relating to the appli\u00ad cation of the principles of good laboratory practice and the verifi\u00ad cation of their applications for tests on chemical substances (2);", "samples": [{"hash": "9edM48m8045", "uri": "https://faolex.fao.org/docs/pdf/eur103352.pdf", "label": "faolex.fao.org", "score": 11.4093084335, "published": false}, {"hash": "9VyXGOGveFP", "uri": "https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02009R1107-20210327&from=EN", "label": "eur-lex.europa.eu", "score": 10.6988363266, "published": false}, {"hash": "b7r7FSAQHcd", "uri": "https://www.legislation.gov.uk/eur/2009/1107/pdfs/eur_20091107_2019-12-14_en.pdf", "label": "www.legislation.gov.uk", "score": 10.1060914993, "published": false}], "snippet_links": [{"key": "annex-i", "type": "definition", "offset": [44, 51]}, {"key": "european-parliament-and-of-the-council", "type": "clause", "offset": [83, 121]}, {"key": "february-2004", "type": "clause", "offset": [128, 141]}, {"key": "provisions-relating-to-the", "type": "clause", "offset": [203, 229]}, {"key": "the-principles", "type": "clause", "offset": [247, 261]}, {"key": "applications-for", "type": "clause", "offset": [322, 338]}, {"key": "chemical-substances", "type": "definition", "offset": [348, 367]}], "hash": "0a835405c766c0a093741dfb398cb414", "id": 4}, {"size": 12, "snippet": "or \"GLP\" shall mean the then current standards for laboratory activities for pharmaceuticals, as set forth in the FD&C Act and applicable regulations and guidances promulgated thereunder, including without limitation the Code of Federal Regulations, as amended from time to time, and any other applicable requirements for laboratory activities under the laws, rules or regulations of the Territory.", "samples": [{"hash": "dIwEOXQ48sL", "uri": "/contracts/dIwEOXQ48sL#good-laboratory-practice", "label": "Manufacturing and Supply Agreement (Corixa Corp)", "score": 18.0, "published": true}, {"hash": "3LrEWxg0qDd", "uri": "/contracts/3LrEWxg0qDd#good-laboratory-practice", "label": "Manufacturing and Supply Agreement (Corixa Corp)", "score": 18.0, "published": true}, {"hash": "gBsySB2XF4D", "uri": "https://www.sec.gov/Archives/edgar/data/1042561/000089102002000464/v80752a1ex10-2.txt", "label": "Commercialization and License Agreement (Corixa Corp)", "score": 6.0, "published": false}], "snippet_links": [{"key": "current-standards", "type": "clause", "offset": [29, 46]}, {"key": "laboratory-activities", "type": "clause", "offset": [51, 72]}, {"key": "fdc-act", "type": "definition", "offset": [114, 122]}, {"key": "applicable-regulations", "type": "definition", "offset": [127, 149]}, {"key": "including-without-limitation", "type": "clause", "offset": [188, 216]}, {"key": "code-of-federal-regulations", "type": "clause", "offset": [221, 248]}, {"key": "as-amended", "type": "definition", "offset": [250, 260]}, {"key": "from-time-to-time", "type": "clause", "offset": [261, 278]}, {"key": "requirements-for", "type": "clause", "offset": [305, 321]}, {"key": "activities-under", "type": "clause", "offset": [333, 349]}, {"key": "the-laws", "type": "definition", "offset": [350, 358]}, {"key": "rules-or-regulations", "type": "definition", "offset": [360, 380]}, {"key": "the-territory", "type": "clause", "offset": [384, 397]}], "hash": "41e2b0aadbba3c85967f105065ee749a", "id": 5}, {"size": 10, "snippet": "means the then current standards for laboratory activities for pharmaceuticals, as set forth in the FD&C Act and applicable regulations promulgated thereunder, as amended from time to time, and such standards of good laboratory practice as are required by the European Union and other Regulatory Authorities in countries in which the Product is intended to be sold, to the extent such standards are not in contravention with United States Good Laboratory Practices.", "samples": [{"hash": "hY4GwfTQfsU", "uri": "/contracts/hY4GwfTQfsU#good-laboratory-practice", "label": "Screening and Analysis Services Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "gnTt1btwBmw", "uri": "/contracts/gnTt1btwBmw#good-laboratory-practice", "label": "Confidentiality Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "e9ylXQju5Nm", "uri": "/contracts/e9ylXQju5Nm#good-laboratory-practice", "label": "Confidentiality Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "current-standards", "type": "clause", "offset": [15, 32]}, {"key": "laboratory-activities", "type": "clause", "offset": [37, 58]}, {"key": "fdc-act", "type": "definition", "offset": [100, 108]}, {"key": "applicable-regulations", "type": "definition", "offset": [113, 135]}, {"key": "as-amended", "type": "definition", "offset": [160, 170]}, {"key": "from-time-to-time", "type": "clause", "offset": [171, 188]}, {"key": "required-by", "type": "definition", "offset": [244, 255]}, {"key": "the-european-union", "type": "clause", "offset": [256, 274]}, {"key": "regulatory-authorities", "type": "clause", "offset": [285, 307]}, {"key": "the-product", "type": "definition", "offset": [330, 341]}, {"key": "to-the-extent", "type": "clause", "offset": [366, 379]}, {"key": "united-states", "type": "clause", "offset": [425, 438]}, {"key": "good-laboratory-practices", "type": "definition", "offset": [439, 464]}], "hash": "64cec05bbd01b21ee5c28d1b9499fd2b", "id": 6}, {"size": 10, "snippet": "means all applicable then-current standards for laboratory activities for pharmaceuticals, as set forth in the FDA\u2019s Good Laboratory Practice regulations as defined in 21 C.F.R. Part 58, the PRC Good Clinical Practice effective as of September 1, 2003, or the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development (OECD), and such standards of good laboratory practice as are required by the equivalent applicable Laws in the relevant Region and other organizations and governmental agencies in countries in which the Licensed Product is intended to be sold by the Party that is subject to such standards.", "samples": [{"hash": "iWX7FNj2A6l", "uri": "/contracts/iWX7FNj2A6l#good-laboratory-practice", "label": "License and Collaboration Agreement (LianBio)", "score": 34.2347717285, "published": true}, {"hash": "957F4wASNpd", "uri": "/contracts/957F4wASNpd#good-laboratory-practice", "label": "License and Collaboration Agreement (Lyra Therapeutics, Inc.)", "score": 32.603012085, "published": true}, {"hash": "dqx1nA5AtKY", "uri": "/contracts/dqx1nA5AtKY#good-laboratory-practice", "label": "License and Collaboration Agreement (Landos Biopharma, Inc.)", "score": 32.57289505, "published": true}], "snippet_links": [{"key": "current-standards", "type": "clause", "offset": [26, 43]}, {"key": "laboratory-activities", "type": "clause", "offset": [48, 69]}, {"key": "the-fda", "type": "clause", "offset": [107, 114]}, {"key": "the-prc", "type": "definition", "offset": [187, 194]}, {"key": "good-clinical-practice", "type": "clause", "offset": [195, 217]}, {"key": "the-organization", "type": "definition", "offset": [299, 315]}, {"key": "and-development", "type": "clause", "offset": [342, 357]}, {"key": "required-by", "type": "definition", "offset": [420, 431]}, {"key": "applicable-laws", "type": "definition", "offset": [447, 462]}, {"key": "relevant-region", "type": "definition", "offset": [470, 485]}, {"key": "other-organizations", "type": "clause", "offset": [490, 509]}, {"key": "governmental-agencies", "type": "clause", "offset": [514, 535]}, {"key": "licensed-product", "type": "definition", "offset": [562, 578]}, {"key": "the-party", "type": "clause", "offset": [605, 614]}, {"key": "subject-to", "type": "clause", "offset": [623, 633]}], "hash": "9f68969c06916780de6c8781d906611e", "id": 7}, {"size": 10, "snippet": "or \u201cGLP\u201d means the current standards for laboratory activities for pharmaceuticals, as set forth in the FDA\u2019s Good Laboratory Practice regulations or the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development, as amended from time to time, and such standards of good laboratory practice as are required by the European Union and other organizations and governmental agencies in countries in which a Product is intended to be sold, to the extent such standards are not less stringent than United States Good Laboratory Practice.", "samples": [{"hash": "iKmSvSXWfUj", "uri": "/contracts/iKmSvSXWfUj#good-laboratory-practice", "label": "License and Supply Agreement (Aeglea BioTherapeutics, Inc.)", "score": 32.3538665771, "published": true}, {"hash": "aeDYH429WRu", "uri": "/contracts/aeDYH429WRu#good-laboratory-practice", "label": "Collaboration and License Agreement (Geron Corp)", "score": 26.1882266998, "published": true}, {"hash": "a8zAFcoVE2u", "uri": "/contracts/a8zAFcoVE2u#good-laboratory-practice", "label": "Collaboration and License Agreement (Achillion Pharmaceuticals Inc)", "score": 24.6043796539, "published": true}], "snippet_links": [{"key": "current-standards", "type": "clause", "offset": [19, 36]}, {"key": "laboratory-activities", "type": "clause", "offset": [41, 62]}, {"key": "the-fda", "type": "clause", "offset": [100, 107]}, {"key": "the-organization", "type": "definition", "offset": [193, 209]}, {"key": "and-development", "type": "clause", "offset": [236, 251]}, {"key": "as-amended", "type": "definition", "offset": [253, 263]}, {"key": "from-time-to-time", "type": "clause", "offset": [264, 281]}, {"key": "required-by", "type": "definition", "offset": [337, 348]}, {"key": "the-european-union", "type": "clause", "offset": [349, 367]}, {"key": "other-organizations", "type": "clause", "offset": [372, 391]}, {"key": "governmental-agencies", "type": "clause", "offset": [396, 417]}, {"key": "to-the-extent", "type": "clause", "offset": [474, 487]}, {"key": "united-states-good-laboratory-practice", "type": "definition", "offset": [531, 569]}], "hash": "5afbb887d286e1c8b7b217df2123be83", "id": 8}, {"size": 10, "snippet": "means current Good Laboratory Practices as specified in the United States Code of Federal Regulations at 21 CFR Part 58 at the time of testing and all applicable ICH guidelines.", "samples": [{"hash": "5tYt6j7DDgf", "uri": "/contracts/5tYt6j7DDgf#good-laboratory-practice", "label": "Development and Commercialization Agreement (Bioverativ Inc.)", "score": 27.967830658, "published": true}, {"hash": "9KhIg4i67dP", "uri": "/contracts/9KhIg4i67dP#good-laboratory-practice", "label": "Development and Commercialization Agreement (Bioverativ Inc.)", "score": 27.8035583496, "published": true}], "snippet_links": [{"key": "good-laboratory-practices", "type": "definition", "offset": [14, 39]}, {"key": "as-specified", "type": "clause", "offset": [40, 52]}, {"key": "united-states-code-of-federal-regulations", "type": "definition", "offset": [60, 101]}, {"key": "cfr-part", "type": "clause", "offset": [108, 116]}, {"key": "at-the-time", "type": "definition", "offset": [120, 131]}, {"key": "ich-guidelines", "type": "definition", "offset": [162, 176]}], "hash": "1d600f0fce7d8f084f0ad5587a176bc9", "id": 9}, {"size": 9, "snippet": "means the applicable Laws governing the conduct of nonclinical laboratory studies, including, as applicable, as promulgated by the FDA in 21 C.F.R. Part 58, or any comparable foreign applicable Laws.", "samples": [{"hash": "lc0VxivJYfk", "uri": "/contracts/lc0VxivJYfk#good-laboratory-practice", "label": "Merger Agreement (Zogenix, Inc.)", "score": 33.049282074, "published": true}, {"hash": "eN30LbpjFJo", "uri": "/contracts/eN30LbpjFJo#good-laboratory-practice", "label": "Merger Agreement (Ra Pharmaceuticals, Inc.)", "score": 30.7713890076, "published": true}, {"hash": "9ZYaQVyYgg8", "uri": "https://zogenixinc.gcs-web.com/static-files/35921d98-9976-49c2-89fb-02fe912b14d7", "label": "zogenixinc.gcs-web.com", "score": 11.024641037, "published": false}], "snippet_links": [{"key": "laws-governing", "type": "clause", "offset": [21, 35]}, {"key": "conduct-of", "type": "clause", "offset": [40, 50]}, {"key": "the-fda", "type": "clause", "offset": [127, 134]}], "hash": "43fb5ab4564d217d9f636666861e6cb8", "id": 10}], "next_curs": "CmUSX2oVc35sYXdpbnNpZGVyY29udHJhY3RzckELEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIhZ29vZC1sYWJvcmF0b3J5LXByYWN0aWNlIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 413, "snippet": "or \u201cGLP\u201d will mean the then current standards for laboratory activities for pharmaceuticals, as set forth in the FDA\u2019s GLP regulations and/or ICH guidelines and applicable regulations.", "title": "Good Laboratory Practice", "id": "good-laboratory-practice", "examples": ["EPA will treat violations of the <strong>Good Laboratory Practice</strong> standards as indicated in \u00a7 792.17 of this chapter.", "The definitions in sec- tion 3 of TSCA and in part 792 of this chapter, <strong>Good Laboratory Practice</strong> Standards, apply to this test guideline.", "The laboratories in Beijing and Guangdong comply with the <strong>Good Laboratory Practice</strong>, or \u201cGLP\u201d, standards.", "Company and its Affiliates have generated, prepared, maintained and retained all Regulatory Materials that are required to be maintained or retained pursuant to and in accordance with Good Clinical Practice, <strong>Good Laboratory Practice</strong>, Good Manufacturing Practice, as applicable, and all other Applicable Laws and all such information is true, complete and correct.", "The University\u2019s Animal Care and Use program does not conduct studies subject to the FDA <strong>Good Laboratory Practice</strong> (GLP) regulations.", "In accordance with Article 12 of this Agreement, the Parties in particular provide each other at least annually with a list of the test facilities which, in the light of the results of the inspections and study audits, conform to <strong>Good Laboratory Practice</strong>, as well as of the dates of inspection or audit and their compliance status.", "In accordance with Article 6 of the Agreement, the Parties shall inform each other in a timely manner when a test facility coming under the terms of section II of this sectoral Chapter which states that it applies <strong>Good Laboratory Practice</strong> fails to conform to such practice to an extent which may jeopardise the integrity or authenticity of any such studies it conducts.", "SuperGen shall ensure that the development activities it undertakes pursuant to Article 3 and Article 4 hereof shall be carried out in accordance with Current Good Clinical Practice, Current <strong>Good Laboratory Practice</strong> and Current Good Manufacturing Practice.", "GLP means all applicable <strong>Good Laboratory Practice</strong> standards, including, as applicable, as set forth in the then current <strong>good laboratory practice</strong> standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, or the equivalent Applicable Laws in the Territory, each as may be amended and applicable from time to time.", "The Parties mutually accept studies and data generated therefrom, produced by the test facilities of the other Party provided they participate in the <strong>Good Laboratory Practice</strong> compliance monitoring programme of that Party in accordance with the principles and provisions stated above."], "related": [["good-laboratory-practices", "Good Laboratory Practices", "<strong>Good Laboratory Practices</strong>"], ["good-manufacturing-practices", "Good Manufacturing Practices", "Good Manufacturing Practices"], ["good-manufacturing-practice", "Good Manufacturing Practice", "Good Manufacturing Practice"], ["current-good-manufacturing-practices", "Current Good Manufacturing Practices", "Current Good Manufacturing Practices"], ["good-clinical-practices", "Good Clinical Practices", "Good Clinical Practices"]], "related_snippets": [], "updated": "2026-05-10T05:39:37+00:00"}, "json": true, "cursor": ""}}